GlassScriptPhysician profile
Vincent Spencer
NPI 1588181853
$3,609.13
in general payments reported to CMS, 2019-2025
19 companies · $1,933 in 2025
The $1,933 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $37.67 · 2023: $531 · 2024: $864 · 2025: $1,933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,328.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $665.91 | 2023-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $406.32 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $403.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $325.51 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $267.93 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $244.14 | 2021-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $191.56 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Tris Pharma INC | $185.90 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $184.42 | 2024-2025 | Azstarys |
| Axsome Therapeutics, INC. | $182.53 | 2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $133.25 | 2025 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $76.08 | 2024 | |
| Lundbeck LLC | $70.91 | 2021-2024 | Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $62.34 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $51.92 | 2024-2025 | Secuado, Xelstrym |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $42.93 | 2025 | |
| Indivior INC. | $41.65 | 2023-2025 | Perseris, Sublocade |
| Bausch Health US, LLC | $40.22 | 2024-2025 | Aplenzin, Wellbutrin |
| Collegium Pharmaceutical, INC. | $32.33 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Spencer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.